U.S. markets close in 3 hours 17 minutes
  • S&P 500

    4,054.47
    -22.10 (-0.54%)
     
  • Dow 30

    34,307.17
    -87.84 (-0.26%)
     
  • Nasdaq

    11,402.80
    -79.65 (-0.69%)
     
  • Russell 2000

    1,886.17
    +4.49 (+0.24%)
     
  • Crude Oil

    80.95
    -0.27 (-0.33%)
     
  • Gold

    1,809.80
    -5.40 (-0.30%)
     
  • Silver

    23.34
    +0.50 (+2.18%)
     
  • EUR/USD

    1.0533
    +0.0004 (+0.04%)
     
  • 10-Yr Bond

    3.5630
    +0.0340 (+0.96%)
     
  • GBP/USD

    1.2291
    +0.0034 (+0.28%)
     
  • USD/JPY

    134.5030
    -0.8030 (-0.59%)
     
  • BTC-USD

    16,952.67
    -28.49 (-0.17%)
     
  • CMC Crypto 200

    402.36
    +0.94 (+0.23%)
     
  • FTSE 100

    7,556.23
    -2.26 (-0.03%)
     
  • Nikkei 225

    27,777.90
    -448.18 (-1.59%)
     

Alnylam Shares Detailed Patisiran Data From Rare Disease Study

  • Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) announced positive results from the APOLLO-B Phase 3 study of patisiran for transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy.

  • The company previously announced topline results from the APOLLO-B study in August 2022.

  • The 12-month study achieved its primary endpoint, with patisiran demonstrating a statistically significant and clinically meaningful benefit on functional capacity, as measured by the 6-Minute Walk Test (6-MWT), compared to placebo, with a median difference of 14.7 meters favoring patisiran.

  • The study also included additional secondary composite outcomes endpoints. A non-significant result was found on the composite endpoint of all-cause mortality, frequency of cardiovascular events, and change from baseline in 6-MWT over 12 months compared to placebo.

  • Patisiran also demonstrated an encouraging safety and tolerability profile in patients with ATTR amyloidosis with cardiomyopathy.

  • Patisiran achieved a rapid and sustained reduction in serum TTR levels, with a mean percent reduction from baseline in serum TTR reduction of 87% at Month 12.

  • On the safety front, Patisiran demonstrated an encouraging safety and tolerability profile, including no cardiac safety concerns relative to the placebo.

  • Most adverse events (AEs) were mild or moderate in severity. The most common treatment-emergent AEs were infusion-related reactions and muscle spasms.

  • Five deaths were observed in patisiran-treated patients and eight in the placebo group.

  • Price Action: ALNY shares are up 2.80% at $214.72 on the last check Thursday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.